Company Filing History:
1 out of 1 
1 out of 2 Years Active: 2017-2019
Title: Innovations by Inventor Li-Ming Huang
Introduction
Li-Ming Huang, a prominent inventor based in Tainan, Taiwan, has made significant contributions to the field of biotechnology. With a portfolio of two patents, he focuses on innovative solutions for health-related issues, particularly hyperglycemia.
Latest Patents
Li-Ming Huang's most recent patent addresses the use of a polysaccharide mixture for the treatment of hyperglycemia. This novel application involves a mixture comprising about 30-50% (wt %) of β(1→3) glucan and β(1→6) glucan, with a molecular weight of at least 500,000. The method suggests administering a dose of about 1 to 1,000 mg/Kg to alleviate symptoms associated with hyperglycemia, including conditions like diabetes mellitus. Another patent disclosed an industrial-scale process for cultivating mycelia, yielding up to 15 Kg of dried mycelia from approximately 300 liters of liquid culture every 30 days. This product is notable for its richness in triterpenoids, which include ganoderic acids known for their potential health benefits.
Career Highlights
Throughout his career, Huang has contributed his expertise to notable companies such as Trineo Biotechnology Co., Ltd. and Double Crane Biotechnology Co., Ltd. His work has had a profound impact on the development of innovative biotechnological products.
Collaborations
Li-Ming Huang has collaborated with several distinguished colleagues, including Cheng-Po Huang and his coworker Cheng-Chiu Tsao, who is also recognized for her contributions to the field. These collaborations have fostered an environment of innovation and creativity, pushing the boundaries of traditional biotechnological approaches.
Conclusion
Li-Ming Huang stands out as a dedicated inventor whose innovative solutions address critical health challenges. His patents demonstrate a commitment to enhancing patient care through the application of biotechnology. As he continues his work, the implications of his research will likely lead to further advancements in the treatment of hyperglycemia and other related disorders.